Engitix Company
Engitix is using its proprietary human organ decellularisation technology to develop tissue engineered products for application in regenerative medicine and drug-target research. EngitixвАЩ core expertise is treatment and research of liver disease using its proprietary technologies for human extra-cellular matrix (ECM) scaffolds and 3D spheroids for bioartificial liver devices. The scaffold technology is applicable to other organs and disease aetiologies including pancreatic and intestine scaffold products.
Founded Date:
2016
Last Funding Type:
Series A
Headquarters:
White City Place, London, UK
Technology:
Regenerative Medicine
Employee Number:
Undisclosed
Industry:
Biomarkers & Targets
Number Of Exists:
Series A
Funding Status:
Early Stage Venture
Investor Type:
Company
Investment Stage:
N/A
Total Funding:
$6.88